Research ExplorerPublicationsHigh Rates of Liver Cirrhosis and Hepatocellular Carcinoma i...

High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities

Standard

High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities. / Bockmann, Jan-Hendrik; Kohsar, Matin; Murray, John M; Hamed, Vanessa; Dandri-Petersen, Maura; Lüth, Stefan; Lohse, Ansgar W; Schulze-Zur-Wiesch, Julian.

In: MICROORGANISMS, Vol. 9, No. 5, 968, 30.04.2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bockmann, J-H, Kohsar, M, Murray, JM, Hamed, V, Dandri-Petersen, M, Lüth, S, Lohse, AW & Schulze-Zur-Wiesch, J 2021, 'High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities', MICROORGANISMS, vol. 9, no. 5, 968. https://doi.org/10.3390/microorganisms9050968

APA

Bockmann, J-H., Kohsar, M., Murray, J. M., Hamed, V., Dandri-Petersen, M., Lüth, S., Lohse, A. W., & Schulze-Zur-Wiesch, J. (2021). High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities. MICROORGANISMS, 9(5), [968]. https://doi.org/10.3390/microorganisms9050968

Vancouver

Bockmann J-H, Kohsar M, Murray JM, Hamed V, Dandri-Petersen M, Lüth S et al. High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities. MICROORGANISMS. 2021 Apr 30;9(5). 968. https://doi.org/10.3390/microorganisms9050968

Bibtex

@article{1d60b3f167844d229cdd22ca3d9a60e2,
title = "High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities",
abstract = "BACKGROUND: The prevalence of metabolic and cardiovascular diseases is rising worldwide. However, little is known about the impact of such disorders on hepatic disease progression in chronic hepatitis B (CHB) during the era of potent nucleo(s)tide analogues (NAs).METHODS: We retrospectively analyzed a single-center cohort of 602 CHB patients, comparing the frequency of liver cirrhosis at baseline and incidences of liver-related events during follow-up (hepatocellular carcinoma, liver transplantation and liver-related death) between CHB patients with a history of diabetes, obesity, hypertension or coronary heart disease (CHD).RESULTS: Rates of cirrhosis at baseline and liver-related events during follow-up (median follow-up time: 2.51 years; NA-treated: 37%) were substantially higher in CHB patients with diabetes (11/23; 3/23), obesity (6/13; 2/13), CHD (7/11; 2/11) or hypertension (15/43; 4/43) compared to CHB patients without the indicated comorbidities (26/509; 6/509). Multivariate analysis identified diabetes as the most significant predictor for cirrhosis (p = 0.0105), while comorbidities did not correlate with liver-related events in pre-existing cirrhosis.CONCLUSION: The combination of metabolic diseases and CHB is associated with substantially increased rates of liver cirrhosis and secondary liver-related events compared to CHB alone, indicating that hepatitis B patients with metabolic comorbidities warrant particular attention in disease surveillance and evaluation of treatment indication.",
author = "Jan-Hendrik Bockmann and Matin Kohsar and Murray, {John M} and Vanessa Hamed and Maura Dandri-Petersen and Stefan L{\"u}th and Lohse, {Ansgar W} and Julian Schulze-Zur-Wiesch",
year = "2021",
month = apr,
day = "30",
doi = "10.3390/microorganisms9050968",
language = "English",
volume = "9",
journal = "MICROORGANISMS",
issn = "2076-2607",
publisher = "MDPI AG",
number = "5",

}

RIS

TY - JOUR

T1 - High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities

AU - Bockmann, Jan-Hendrik

AU - Kohsar, Matin

AU - Murray, John M

AU - Hamed, Vanessa

AU - Dandri-Petersen, Maura

AU - Lüth, Stefan

AU - Lohse, Ansgar W

AU - Schulze-Zur-Wiesch, Julian

PY - 2021/4/30

Y1 - 2021/4/30

N2 - BACKGROUND: The prevalence of metabolic and cardiovascular diseases is rising worldwide. However, little is known about the impact of such disorders on hepatic disease progression in chronic hepatitis B (CHB) during the era of potent nucleo(s)tide analogues (NAs).METHODS: We retrospectively analyzed a single-center cohort of 602 CHB patients, comparing the frequency of liver cirrhosis at baseline and incidences of liver-related events during follow-up (hepatocellular carcinoma, liver transplantation and liver-related death) between CHB patients with a history of diabetes, obesity, hypertension or coronary heart disease (CHD).RESULTS: Rates of cirrhosis at baseline and liver-related events during follow-up (median follow-up time: 2.51 years; NA-treated: 37%) were substantially higher in CHB patients with diabetes (11/23; 3/23), obesity (6/13; 2/13), CHD (7/11; 2/11) or hypertension (15/43; 4/43) compared to CHB patients without the indicated comorbidities (26/509; 6/509). Multivariate analysis identified diabetes as the most significant predictor for cirrhosis (p = 0.0105), while comorbidities did not correlate with liver-related events in pre-existing cirrhosis.CONCLUSION: The combination of metabolic diseases and CHB is associated with substantially increased rates of liver cirrhosis and secondary liver-related events compared to CHB alone, indicating that hepatitis B patients with metabolic comorbidities warrant particular attention in disease surveillance and evaluation of treatment indication.

AB - BACKGROUND: The prevalence of metabolic and cardiovascular diseases is rising worldwide. However, little is known about the impact of such disorders on hepatic disease progression in chronic hepatitis B (CHB) during the era of potent nucleo(s)tide analogues (NAs).METHODS: We retrospectively analyzed a single-center cohort of 602 CHB patients, comparing the frequency of liver cirrhosis at baseline and incidences of liver-related events during follow-up (hepatocellular carcinoma, liver transplantation and liver-related death) between CHB patients with a history of diabetes, obesity, hypertension or coronary heart disease (CHD).RESULTS: Rates of cirrhosis at baseline and liver-related events during follow-up (median follow-up time: 2.51 years; NA-treated: 37%) were substantially higher in CHB patients with diabetes (11/23; 3/23), obesity (6/13; 2/13), CHD (7/11; 2/11) or hypertension (15/43; 4/43) compared to CHB patients without the indicated comorbidities (26/509; 6/509). Multivariate analysis identified diabetes as the most significant predictor for cirrhosis (p = 0.0105), while comorbidities did not correlate with liver-related events in pre-existing cirrhosis.CONCLUSION: The combination of metabolic diseases and CHB is associated with substantially increased rates of liver cirrhosis and secondary liver-related events compared to CHB alone, indicating that hepatitis B patients with metabolic comorbidities warrant particular attention in disease surveillance and evaluation of treatment indication.

U2 - 10.3390/microorganisms9050968

DO - 10.3390/microorganisms9050968

M3 - SCORING: Journal article

C2 - 33946154

VL - 9

JO - MICROORGANISMS

JF - MICROORGANISMS

SN - 2076-2607

IS - 5

M1 - 968

ER -